Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748371 · ClinicalTrials.gov registry record · Phase 4
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
A Phase 4 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT00748371 is a Phase 4 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 51 participants.
The verdict
NCT00748371, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke. We are investigating how aspirin works on regulating platelets and thromboxane over time at different doses. We hope to find the best dose of aspirin and/or other medications to help people who are at risk for heart attack or stroke.
Interventions
- DRUG placebo
- DRUG aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2004-06 |
| Est. Completion | 2011-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748371
The ClinicalTrials.gov registry entry for NCT00748371 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00748371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748371 about?
NCT00748371 is a clinical study titled "Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration". Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke. We are investigating how aspirin works on regulating platelets and thromboxane over time at different doses. We hope to find the best dose of aspirin and/or other medications to help ...
What is the current status of trial NCT00748371?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2004-06. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00748371?
The interventions under investigation include: placebo (DRUG), aspirin (DRUG).
Who is sponsoring clinical trial NCT00748371?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.